PRESS COMMENT: A new licence announced this week between the University of Surrey and Randox could bring to market a urine test that will help with the early detection of prostate cancer.
According to scientists at the University of Surrey the test is a more reliable way of detecting prostate cancer. The team focused on the EN2 protein produced by prostate cancer which is secreted into urine.
Dr Matthew Hobbs, Deputy Director of Research at Prostate Cancer UK says;
“The diagnostic tests currently available to doctors can’t easily differentiate deadly forms of prostate cancer which require immediate radical treatment from less harmful cancers that may require no treatment at all. This lack of clarity means that many of the 40,000 men who are diagnosed with the disease each year are faced with making difficult decisions on which treatment path to take without all the information they need. There is a desperate need for better tests that can immediately identify men in need of urgent treatment, whilst saving others from having to endure treatment unnecessarily.
“The results of research into the EN2 biomarker are encouraging and add weight to the theory that in the future testing for certain markers in the urine may be able to give a good indication as to whether a man has prostate cancer – and whether or not it is an aggressive form. However, much larger trials that involve a broader sample of men and follow their health for several years are needed before we can say for sure that a test for this marker is one that will work in clinical practice. Even then, it is unlikely that this test on its own will give a reliable enough result to be used on its own and will most probably be used in addition to current tests.”
For further information contact the Prostate Cancer UK press office: 020 3310 7188 or email@example.com.